{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:54:48Z","timestamp":1792212888649,"version":"4.4.0"},"reference-count":164,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1002\/jps.21179","type":"journal-article","created":{"date-parts":[[2007,9,24]],"date-time":"2007-09-24T12:47:58Z","timestamp":1190638078000},"page":"2405-2425","source":"Crossref","is-referenced-by-count":271,"title":["Amphotericin B Formulations and Drug Targeting"],"prefix":"10.1016","volume":"97","author":[{"given":"J.J.","family":"Torrado","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Espada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Torrado-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1002\/jps.21179_bb0010","series-title":"Amphotericin B, its production and its salts","author":"Dutcher","year":"1959"},{"key":"10.1002\/jps.21179_bb0015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00253-005-1955-9","article-title":"Amphotericin B","volume":"68","author":"Lemke","year":"2005","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1002\/jps.21179_bb0020","series-title":"Amphotericin B. The Merck index","first-page":"2194","author":"Windholz","year":"1983"},{"key":"10.1002\/jps.21179_bb0025","series-title":"The Goodman & Gilman's pharmacological basis of therapeutics","first-page":"1175","article-title":"Antimicrobial agents: Antifungal agents","author":"Bennett","year":"1995"},{"key":"10.1002\/jps.21179_bb0030","series-title":"Veterinary drug handbook","author":"Plumb","year":"1999"},{"key":"10.1002\/jps.21179_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0005-2736(01)00416-3","article-title":"Interactions of the drug amphotericin b with phospholipid membranes containing or not ergosterol: New insights into the role of ergosterol","volume":"1558","author":"Milhaud","year":"2002","journal-title":"Biochim Biophys Acta"},{"key":"10.1002\/jps.21179_bb0040","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0005-2736(80)90074-7","article-title":"Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B: Lipid state and cholesterol content dependence","volume":"599","author":"Bolard","year":"1980","journal-title":"Biochim Byophys Acta"},{"key":"10.1002\/jps.21179_bb0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0927-7765(98)00033-2","article-title":"Interaction of amphotericin B withpolymeric colloids. A spectroscopy study","volume":"11","author":"Espuelas","year":"1998","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1002\/jps.21179_bb0050","first-page":"1","article-title":"Spectroscopic investigation of the aggregation state of amphotericin B during loading, freeze-drying, and reconstitution of polymeric micelles","volume":"7","author":"Adams","year":"2004","journal-title":"J Pharm Pharmaceut Sci"},{"key":"10.1002\/jps.21179_bb0055","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/10611860400006596","article-title":"Amphotericin B molecular organization as an essential factor to improve activity\/toxicity ratio in the treatment of visceral leishmaniasis","volume":"12","author":"S\u00e1nchez-Brunete","year":"2004","journal-title":"J Drug Target"},{"key":"10.1002\/jps.21179_bb0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0168-3659(02)00347-4","article-title":"Relative aggregation state and hemolytic activity of amphotericin B encapsulated by poly(ethylene oxide)-block-poly(N-hexyl-L-aspartamide)-acyl conjugate micelles: Effects of acyl chain length","volume":"87","author":"Adams","year":"2003","journal-title":"J Control Release"},{"key":"10.1002\/jps.21179_bb0065","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/bip.1981.360200802","article-title":"Structure of amphotericin B aggregates as revealed by UV and CD spectroscopies","volume":"20","author":"Ernst","year":"1981","journal-title":"Biopolymers"},{"key":"10.1002\/jps.21179_bb0070","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/bip.360220312","article-title":"Structure of amphotericin B aggregates based on calculations of optical spectra","volume":"22","author":"Hemenger","year":"1983","journal-title":"Biopolymers"},{"key":"10.1002\/jps.21179_bb0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/jcis.1993.1230","article-title":"Spontaneous organization of amphotericin B in aqueous medium","volume":"158","author":"Barwicz","year":"1993","journal-title":"J Colloid Interface Sci"},{"key":"10.1002\/jps.21179_bb0080","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/bip.360280908","article-title":"Aggregation of amphotericin B in the presence of \u03b3-cyclodextrin","volume":"28","author":"Kajt\u00e1r","year":"1989","journal-title":"Biopolymers"},{"key":"10.1002\/jps.21179_bb0085","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1128\/AAC.36.11.2518","article-title":"Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes","volume":"36","author":"Legrand","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0090","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1128\/AAC.38.2.300","article-title":"Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: Molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses","volume":"38","author":"Brajtburg","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0095","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/jps.20038","article-title":"Evaluation of the relationship of the molecular aggregation state of amphotericin B in medium to its genotoxic potential","volume":"93","author":"Egito","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21179_bb0100","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1139\/o88-024","article-title":"Effect of the aggregation state of amphotericin b on its interaction with ergosterol","volume":"66","author":"Gruda","year":"1988","journal-title":"Biochem Cell Biol"},{"key":"10.1002\/jps.21179_bb0105","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02427375","article-title":"Influence of net charge on the aggregation and solubility behaviour of amphotericin B and its derivatives in aqueous media","volume":"18","author":"Mazerski","year":"1990","journal-title":"Eur Biophys J"},{"key":"10.1002\/jps.21179_bb0110","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0005-2736(93)90139-Q","article-title":"CD and NMR studies on the aggregation of amphotericin B in solution","volume":"1148","author":"Balakrishnan","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"10.1002\/jps.21179_bb0115","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0006-291X(88)90232-X","article-title":"Effects of the detergent sucrose monolaureate on binding of amphotericin B to sterol and its toxicity for cells","volume":"154","author":"Gruda","year":"1988","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1002\/jps.21179_bb0120","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.2042-7158.1988.tb05260.x","article-title":"Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes","volume":"40","author":"Forster","year":"1988","journal-title":"J Pharm Pharmacol"},{"key":"10.1002\/jps.21179_bb0125","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0005-2736(90)90305-8","article-title":"The effect of surfactants on the aggregation state of amphotericin B","volume":"1030","author":"Tancr\u00e8de","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"10.1002\/jps.21179_bb0130","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.35.1.24","article-title":"Structure-activity study of inhibition of amphotericin B (Fungizone) binding to sterols, toxicity to cells, and lethality to mice by esters of sucrose","volume":"35","author":"Gruda","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0135","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1128\/CMR.9.4.512","article-title":"Carrier effects on biological activity of amphotericin B","volume":"9","author":"Brajtburg","year":"1996","journal-title":"Clin Microbiol Rev"},{"key":"10.1002\/jps.21179_bb0140","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/10611869708995847","article-title":"Release of amphotericin B from delivery systems and its action against fungal and mammalian cells","volume":"4","author":"Legrand","year":"1997","journal-title":"J Drug Target"},{"key":"10.1002\/jps.21179_bb0145","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/1520-6017(200012)89:12<1589::AID-JPS10>3.0.CO;2-6","article-title":"The effect of serum albumin on the aggregation state and toxicity of amphotericin B","volume":"89","author":"Aramwit","year":"2000","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21179_bb0150","first-page":"125","article-title":"Block copolymer micelles for the encapsulation and delivery of amphotericin B","volume":"91","author":"Lavasanifar","year":"2002","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21179_bb0155","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1021\/bm0257614","article-title":"Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity","volume":"4","author":"Adams","year":"2003","journal-title":"Biomacromolecules"},{"key":"10.1002\/jps.21179_bb0160","first-page":"386","article-title":"PEG-phospholipid micelles for the delivery of amphotericin B","volume":"101","author":"Vakil","year":"2005","journal-title":"J Control Release"},{"key":"10.1002\/jps.21179_bb0165","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ijpharm.2005.11.031","article-title":"Encapsulation of amphotericin B in poly(ethylene glycol)-block-poly(\u03b5-caprolactone-co-trimethylenecarbonate) polymeric micelles","volume":"309","author":"Vandermeulen","year":"2006","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21179_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0301-4622(96)02241-7","article-title":"Physicochemical properties of the heat-induced superaggregates of amphotericin B","volume":"66","author":"Gaboriau","year":"1997","journal-title":"Biophys Chem"},{"key":"10.1002\/jps.21179_bb0175","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1073\/pnas.85.16.6122","article-title":"Unusual lipid structures selectivity reduce the toxicity of amphotericin B","volume":"85","author":"Janoff","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/jps.21179_bb0180","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0005-2736(93)90246-V","article-title":"Temperature effects on the aggregation state and activity of amphotericin B","volume":"1152","author":"Lambing","year":"1993","journal-title":"Biochim Biophys Acta"},{"key":"10.1002\/jps.21179_bb0185","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1021\/bi00237a011","article-title":"One-sided action of amphotericin B on cholesterol containing membranes is determined by its self association in the medium","volume":"30","author":"Bolard","year":"1991","journal-title":"Biochemistry"},{"key":"10.1002\/jps.21179_bb0190","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0009-3084(96)02652-7","article-title":"The effect of aggregation state of amphotericin B on its interactions with cholesterol or ergosterol containing phosphatidylcholine monolayers","volume":"85","author":"Barwicz","year":"1997","journal-title":"Chem Phys Lipids"},{"key":"10.1002\/jps.21179_bb0195","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1128\/AAC.36.10.2310","article-title":"Effect of the aggregation state of amphotericin B on its toxicity to mice","volume":"36","author":"Barwicz","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0200","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/AAC.41.11.2345","article-title":"Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: A new way to improve its therapeutic index","volume":"41","author":"Gaboriau","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0205","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1128\/AAC.44.6.1598-1603.2000","article-title":"Mild heating of amphotericin B-deoxycholate: Effects on ultraestructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice","volume":"44","author":"van Etten","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0210","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1128\/AAC.48.1.333-336.2004","article-title":"Effect of heat-treated amphotericin B on renal and fungal cytotoxicity","volume":"48","author":"Barlett","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0215","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jac\/42.6.779","article-title":"In vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B (Fungizone) obtained by mild heating","volume":"42","author":"Petit","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/jps.21179_bb0220","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.43.2.390","article-title":"Activity of a heat-induced reformulation of amphotericin B deoxycholate (Fungizone) against Leishmania donovani","volume":"43","author":"Petit","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/ps010310","article-title":"Activity and kinetics of dissociation and transfer of amphotericin B from a novel delivery form","volume":"1","author":"Baas","year":"1999","journal-title":"AAPS Pharmsci"},{"key":"10.1002\/jps.21179_bb0230","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/1520-6017(200102)90:2<124::AID-JPS3>3.0.CO;2-X","article-title":"Heat-induced superaggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-alpha","volume":"90","author":"Hartsel","year":"2001","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21179_bb0235","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1023\/A:1013090011952","article-title":"The effect of serum albumin on amphotericin B aggregate structure and activity","volume":"18","author":"Hartsel","year":"1983","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21179_bb0240","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jac\/dkg070","article-title":"Heat-induced superaggregation of amphotericin B attenuates its ability to induce cytokine and chemokine production in the human monocytic cell line THP-1","volume":"51","author":"Rogers","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/jps.21179_bb0245","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1128\/AAC.45.7.2060-2063.2001","article-title":"Heat treatment of amphotericin B modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits","volume":"45","author":"Kwong","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0250","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1358\/dot.2004.40.2.799425","article-title":"Lipid-based formulations of amphotericin B","volume":"40","author":"Veerareddy","year":"2004","journal-title":"Drugs Today"},{"key":"10.1002\/jps.21179_bb0255","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1021\/bi962894z","article-title":"The formation of amphotericin B ion channels in lipid bilayers","volume":"38","author":"Fuji","year":"1997","journal-title":"Biochemistry"},{"key":"10.1002\/jps.21179_bb0260","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1128\/AAC.41.10.2089","article-title":"Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis","volume":"41","author":"Mullen","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0265","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1177\/00912700122010942","article-title":"Pharmacokinetics, excretion and mass balance of 14C after administration of 14C-cholesterol-labeled Ambisome to healthy volunteers","volume":"41","author":"Bekersky","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jps.21179_bb0270","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (Ambisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0275","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: Time for a new \u201cgold standard\u201d","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1002\/jps.21179_bb0280","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ijantimicag.2006.03.013","article-title":"What is the current and future status of conventional amphotericin B?","volume":"27S","author":"Kleinberg","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1002\/jps.21179_bb0285","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/0006-291X(73)91494-0","article-title":"Potassium fluxes, first indication of membrane damage in microorganism","volume":"54","author":"Lambert","year":"1973","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1002\/jps.21179_bb0290","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0005-2736(89)90417-3","article-title":"Concentration dependent dual effect of the monolauryl ester of sucrose on the antifungal activity and absorption spectra of amphotericin B (Fungizone)","volume":"985","author":"Brajtburg","year":"1989","journal-title":"Biochim Biophys Acta"},{"key":"10.1002\/jps.21179_bb0295","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","article-title":"Amphotericin B. 30 tears of clinical experience","volume":"12","author":"Gallis","year":"1990","journal-title":"Rev Infect Dis"},{"key":"10.1002\/jps.21179_bb0300","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/313498","article-title":"Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis","volume":"29","author":"Wingard","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1002\/jps.21179_bb0305","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bmj.322.7286.579","article-title":"Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 h: Randomised controlled trial","volume":"322","author":"Eriksson","year":"2001","journal-title":"Br Med J"},{"key":"10.1002\/jps.21179_bb0310","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/ki.1991.214","article-title":"Effect of salt supplementation on amphotericin B nephrotoxicity","volume":"40","author":"Llanos","year":"1991","journal-title":"Kidney Int"},{"key":"10.1002\/jps.21179_bb0315","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/mmy.41.1.15.19","article-title":"Pharmacokinetics of amphotericin B in serum and tissues in mice treated with amphotericin B-Intralipid","volume":"41","author":"Shadkchan","year":"2003","journal-title":"Med Mycol"},{"key":"10.1002\/jps.21179_bb0320","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/infdis\/158.5.1065","article-title":"An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis","volume":"158","author":"Kirsh","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1002\/jps.21179_bb0325","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/BF01989977","article-title":"Clinical evaluation of a new lipid based delivery system for intravenous administration of amphotericin B","volume":"11","author":"Caillot","year":"1992","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1002\/jps.21179_bb0330","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/jac\/31.1.161","article-title":"Efficacy and tolerance of an amphotericin B lipid (intralipid) emulsion in the treatment of candidaemia in neutropenic patients","volume":"31","author":"Caillot","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/jps.21179_bb0335","first-page":"806","article-title":"Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients","volume":"31","author":"Moreau","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/jps.21179_bb0340","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/jac\/31.5.806","article-title":"Toxicity of amphotericin B emulsion formulations","volume":"31","author":"Washington","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/jps.21179_bb0345","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1042\/bj1860591","article-title":"Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro","volume":"186","author":"Kirby","year":"1980","journal-title":"Biochem J"},{"key":"10.1002\/jps.21179_bb0350","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/49.suppl_1.21","article-title":"AmBisome: Liposomal formulation, structure, mechanism of action and preclinical experience","volume":"49","author":"Moore","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/jps.21179_bb0355","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/319211","article-title":"Mortality and costs of acute renal failure associated with amphotericin B therapy","volume":"32","author":"Bates","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1002\/jps.21179_bb0360","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/28.suppl_B.93","article-title":"Liposomal amphotericin B (Ambisome) in the treatment of fungal infections in neutropenic patients","volume":"28","author":"Chopra","year":"1981","journal-title":"J Antimicrob Agents"},{"key":"10.1002\/jps.21179_bb0365","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/28.suppl_B.83","article-title":"Liposomal amphotericin B (AmBisome): Safety data from a phase II\/III clinical trial","volume":"28","author":"Meunier","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/jps.21179_bb0370","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2174\/1381612023395853","article-title":"Pharmaceutical design of the liposomal antimicrobial agents for infectious disease","volume":"8","author":"Moribe","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1002\/jps.21179_bb0375","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1023\/A:1011011215418","article-title":"Lyophilized lecithin-based oil-water microemulsions as a new and low toxic delivery system for Amphotericin B","volume":"18","author":"Moreno","year":"2001","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21179_bb0380","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/jps.10412","article-title":"Lecithin-based oil-in-water microemulsions for parenteral use: Pseudoternary phase diagrams, characterization, and toxicity studies","volume":"92","author":"Moreno","year":"2003","journal-title":"J Pham Sci"},{"key":"10.1002\/jps.21179_bb0385","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/jps.10065","article-title":"Amphotericin B in oil-water lecithin-based microemulsions: Formulation and toxicity evaluation","volume":"91","author":"Brime","year":"2002","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21179_bb0390","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jac\/dkg266","article-title":"Comparative pharmacokinetics and safety of a novel lyophilized Amphotericin B lecithin-based oil-water microemulsion and Amphotericin B-deoxycholate in animal models","volume":"52","author":"Brime","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/jps.21179_bb0395","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejps.2004.04.008","article-title":"Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and deoxycholate-amphotericin B in immunocompetent and neutropenic mice infected with Candida albicans","volume":"22","author":"Brime","year":"2004","journal-title":"Eur J Pharm Sci"},{"key":"10.1002\/jps.21179_bb0400","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0005-2736(75)90299-0","article-title":"Cochleate lipid cylinders: Formation by fusion of unilamellar lipid vesicles","volume":"384","author":"Papahadjopoulus","year":"1975","journal-title":"Biochim Byophys Acta"},{"key":"10.1002\/jps.21179_bb0405","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0076-6879(05)91018-5","article-title":"Drug delivery by lipid cochleates","volume":"391","author":"Zarif","year":"2005","journal-title":"Methods Enzymol"},{"key":"10.1002\/jps.21179_bb0410","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/jac\/dki455","article-title":"Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity agains Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects","volume":"57","author":"Charvalos","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/jps.21179_bb0415","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/10611860500097107","article-title":"Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B","volume":"13","author":"S\u00e1nchez-Brunete","year":"2005","journal-title":"J Drug Target"},{"key":"10.1002\/jps.21179_bb0420","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1128\/AAC.48.9.3246-3252.2004","article-title":"Treatment of experimental visceral leishmaniasis with amphotericin b in stable albumin microspheres","volume":"48","author":"S\u00e1nchez-Brunete","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0425","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00118-6","article-title":"Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future","volume":"47","author":"M\u00fcller","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1002\/jps.21179_bb0430","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0378-5173(02)00686-5","article-title":"Formulation of amphotericin B as nanosuspensions for oral administration","volume":"254","author":"Kayser","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1002\/jps.21179_bb0435","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0927-7765(99)00156-3","article-title":"\u201cStealth\u201d corona-core nanoparticles surface modified by polyethylene glycol (PEG): Influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption","volume":"18","author":"Gref","year":"2000","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1002\/jps.21179_bb0440","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/026520499289185","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery: II. Drug incorporation and physicochemical characterization","volume":"16","author":"Schwarz","year":"1999","journal-title":"J Microencapsul"},{"key":"10.1002\/jps.21179_bb0445","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0169-409X(02)00118-7","article-title":"Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations","volume":"54","author":"M\u00fcller","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1002\/jps.21179_bb0450","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/AAC.43.3.471","article-title":"In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus","volume":"43","author":"Otsubo","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0455","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jac\/dkg351","article-title":"Polymeric carriers of amphotericin B: In vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice","volume":"52","author":"Espuelas","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/jps.21179_bb0460","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1128\/AAC.44.9.2356-2360.2000","article-title":"Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis","volume":"44","author":"Santangelo","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0465","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/mp0601143","article-title":"Physicochemical characterization of molecular assemblies of miltefosine and amphotericin B","volume":"4","author":"M\u00e9nez","year":"2007","journal-title":"Mol Pharm"},{"key":"10.1002\/jps.21179_bb0470","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1128\/AAC.00837-06","article-title":"Interaction between miltefosine and amphotericin B: Consequences for their activities towards intestinal ephitelial cells and Leishmania donovani promastigotes in vitro","volume":"50","author":"M\u00e9nez","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0475","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF01695915","article-title":"Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia","volume":"68","author":"Hertenstein","year":"1994","journal-title":"Ann Hematol"},{"key":"10.1002\/jps.21179_bb0480","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF01726364","article-title":"Tolerance and efficacy of amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients","volume":"16","author":"Erjavec","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1002\/jps.21179_bb0485","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1021\/js9604218","article-title":"Disposition of aerolized liposomal amphotericin B","volume":"86","author":"Lambros","year":"1997","journal-title":"J Pharm Sci"},{"key":"10.1002\/jps.21179_bb0490","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijantimicag.2006.03.018","article-title":"Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections","volume":"27","author":"Drew","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1002\/jps.21179_bb0495","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0142-9612(92)90142-B","article-title":"Body distribution of fully biodegradable [14C]-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats","volume":"13","author":"Bazile","year":"1992","journal-title":"Biomaterials"},{"key":"10.1002\/jps.21179_bb0500","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1128\/AAC.40.3.609","article-title":"Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin b in a group of patients with neutropenia","volume":"40","author":"Ayestaran","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0505","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","article-title":"Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (Ambisome) and amphotericin B deoxycholate","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0510","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/AAC.13.2.271","article-title":"Amphotericin B. Pharmacokinetics in humans","volume":"13","author":"Aktinson","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0515","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1023\/A:1011923704731","article-title":"Elucidation of human amphotericin B pharmacokinetics: Identification of a new potential factor affecting interspecies pharmacokinetic scaling","volume":"15","author":"Robbie","year":"1998","journal-title":"Pharm Res"},{"key":"10.1002\/jps.21179_bb0520","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0525","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/jac\/33.2.203","article-title":"Administering amphotericin B\u2014A practical approach","volume":"33","author":"Khoo","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/jps.21179_bb0530","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1128\/AAC.35.4.615","article-title":"Amphotericin B lipid complex therapy of experimental fungal infections in mice","volume":"35","author":"Clark","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0535","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/28.suppl_B.49","article-title":"Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents","volume":"28","author":"Proffitt","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/jps.21179_bb0540","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1128\/AAC.35.6.1208","article-title":"Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats","volume":"35","author":"Fielding","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0545","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/j.1552-4604.1998.tb04464.x","article-title":"AmBisome (liposomal amphotericin B): A comparative review","volume":"38","author":"Boswell","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jps.21179_bb0550","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1185\/030079904125003179","article-title":"Efficacy, safety and cost-effectiveness of amphotericine B lipid complex (ABLC): A review of the literature","volume":"20","author":"Martino","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1002\/jps.21179_bb0555","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00003088-198308010-00002","article-title":"Clinical pharmacokinetics of systemic antifungal drugs","volume":"8","author":"Daneshmend","year":"1983","journal-title":"Clin Pharmacokinet"},{"key":"10.1002\/jps.21179_bb0560","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-199223040-00004","article-title":"Liposomal and lipid formulations of amphotericin B","volume":"23","author":"Janknegt","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"10.1002\/jps.21179_bb0565","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/infdis\/164.2.418","article-title":"Comparative safety, tolerance and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycholate in healthy male volunteers","volume":"164","author":"Kan","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1002\/jps.21179_bb0570","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.2042-7158.1991.tb03189.x","article-title":"Tissue distribution of amphotericin B lipid complex in laboratory animals","volume":"43","author":"Olsen","year":"1991","journal-title":"J Pharm Pharmacol"},{"key":"10.1002\/jps.21179_bb0575","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1128\/AAC.50.2.674-684.2006","article-title":"Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0580","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1128\/AAC.00315-06","article-title":"Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspegillosis model","volume":"50","author":"Olson","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0585","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1128\/AAC.41.10.2201","article-title":"Pharmacokinetic profile of Abelcet (amphotericin B lipid complex injection): Combined experience from phase I and phase II studies","volume":"41","author":"Adedoyin","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0590","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1128\/AAC.44.10.2900-2902.2000","article-title":"A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections","volume":"44","author":"Adedoyin","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0595","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1358\/dot.1996.32.5.379050","article-title":"Amphotericin B lipid complex: Review of safety, pharmacokinetic and efficacy","volume":"32","author":"Dix","year":"1996","journal-title":"Drugs Today"},{"key":"10.1002\/jps.21179_bb0600","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1128\/AAC.36.2.299","article-title":"Relationship of pharmacokinetics and drug distribution in tissue to incrased safety of amphotericin B colloidal dispersion in dogs","volume":"36","author":"Fielding","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0605","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2710.1993.tb00605.x","article-title":"Amphotericyn B and its delivery by liposomal and lipid formulations","volume":"18","author":"Gates","year":"1993","journal-title":"J Clin Pharmacy Ther"},{"key":"10.1002\/jps.21179_bb0610","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1128\/AAC.35.6.1029","article-title":"Single-dose pharmacokinetics and tolerance of a cholesteryl sulfate complex of amphotericin B administered to healthy volunteers","volume":"35","author":"Sanders","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0615","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/jac\/33.5.907","article-title":"Clinical use of liposomal and lipid complexes amphotericin B","volume":"33","author":"de Marie","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1002\/jps.21179_bb0620","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1128\/AAC.42.9.2391","article-title":"Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (Ambisome) in neutropenic patients","volume":"42","author":"Walsh","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0625","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1128\/AAC.38.4.713","article-title":"Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits","volume":"38","author":"Lee","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0630","first-page":"179","article-title":"Effect of tissue penetration on AmBisome efficacy","volume":"4","author":"Adler-Moore","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1002\/jps.21179_bb0635","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2005.10.010","article-title":"High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: A pharmacokinetic study","volume":"12","author":"Mehta","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1002\/jps.21179_bb0640","unstructured":"Lewis RE.2007.http:\/\/www.doctorfungus.org\/thedrugs\/"},{"key":"10.1002\/jps.21179_bb0645","first-page":"197","article-title":"NCCN practice guidelines for fever and neutropenia","volume":"13","author":"Rubenstein","year":"1999","journal-title":"Oncology-Ny"},{"key":"10.1002\/jps.21179_bb0650","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1200\/JCO.2000.18.12.2476","article-title":"Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients","volume":"18","author":"Cagnoni","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1002\/jps.21179_bb0655","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/00019053-200422050-00004","article-title":"Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections","volume":"22","author":"Kuti","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1002\/jps.21179_bb0660","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","article-title":"Liposomal amphotericin B for the treatment of visceral leishmaniasis","volume":"43","author":"Bern","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1002\/jps.21179_bb0665","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0149-2918(03)80125-X","article-title":"A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations","volume":"25","author":"Barrett","year":"2003","journal-title":"Clin Therap"},{"key":"10.1002\/jps.21179_bb0670","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1086\/429333","article-title":"Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients","volume":"40","author":"Chandrasekar","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1002\/jps.21179_bb0675","doi-asserted-by":"crossref","first-page":"S409","DOI":"10.1086\/429337","article-title":"Successful use of amphotericin B lipid complex in the treatment of cryptococcosis","volume":"40","author":"Baddour","year":"2005","journal-title":"Clin Infec Dis"},{"key":"10.1002\/jps.21179_bb0680","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.1086\/429335","article-title":"Study of renal safety in amphotericin B lipid complexes-treated patients","volume":"40","author":"Alexander","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1002\/jps.21179_bb0685","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1002\/jps.21179_bb0690","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Eng J Med"},{"key":"10.1002\/jps.21179_bb0695","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Eng J Med"},{"key":"10.1002\/jps.21179_bb0700","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1002\/jps.21179_bb0705","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10096-005-1281-2","article-title":"Adverse effects of antifungal therapies in invasive fungal infections: Review and meta-analysis","volume":"24","author":"Girois","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1002\/jps.21179_bb0710","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1002\/jps.21179_bb0715","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/BF01975823","article-title":"Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B","volume":"10","author":"Anaissie","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1002\/jps.21179_bb0720","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1128\/AAC.42.6.1412","article-title":"Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations","volume":"42","author":"Johnson","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.21179_bb0725","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0924-8579(99)00133-8","article-title":"Comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis","volume":"13","author":"Yardley","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"10.1002\/jps.21179_bb0730","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1517\/14656566.4.8.1277","article-title":"The lipid formulations of amphotericin B","volume":"4","author":"Herbrecht","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1002\/jps.21179_bb0735","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1097\/00003246-200007000-00056","article-title":"Pulmonary extraction and accumulation of lipid formulations of amphotericin B","volume":"28","author":"Matot","year":"2000","journal-title":"Crit Care Med"},{"key":"10.1002\/jps.21179_bb0740","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/clinids\/23.3.608","article-title":"Therapeutic outcome in invasive aspergillosis","volume":"23","author":"Denning","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1002\/jps.21179_bb0745","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0145-2126(96)00075-6","article-title":"Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?","volume":"21","author":"Mehta","year":"1997","journal-title":"Leukemia Res"},{"key":"10.1002\/jps.21179_bb0750","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00005792-200007000-00006","article-title":"Invasive aspergillosis. Disease spectrum, treatment practices and outcomes. 13 Aspergillus Study group","volume":"79","author":"Patterson","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1002\/jps.21179_bb0755","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1517\/14656566.4.11.2099","article-title":"Amphotericin B lipid complex for the treatment of invasive fungal infections","volume":"4","author":"Linden","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"10.1002\/jps.21179_bb0760","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00002030-199712000-00010","article-title":"Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated crytococcal meningitis","volume":"11","author":"Leenders","year":"1997","journal-title":"AIDS"},{"key":"10.1002\/jps.21179_bb0765","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/clinids\/22.2.315","article-title":"Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS","volume":"22","author":"Sharkey","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1002\/jps.21179_bb0770","first-page":"399","article-title":"Current scenario of drug development for leishmaniasis","volume":"123","author":"Croft","year":"2006","journal-title":"Indian J Med Res"},{"key":"10.1002\/jps.21179_bb0775","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/00001432-200212000-00007","article-title":"Advances in the treatment of leishmaniasis","volume":"15","author":"Sundar","year":"2002","journal-title":"Curr Opin Infect Dis"},{"key":"10.1002\/jps.21179_bb0780","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.pt.2005.08.026","article-title":"Chemotherapy of trypanosomiases and leishmaniasis","volume":"21","author":"Croft","year":"2005","journal-title":"Trends Parasitol"},{"key":"10.1002\/jps.21179_bb0785","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.2165\/00003495-200464170-00004","article-title":"Amphotericin B lipid complexes: In visceral leishmaniasis","volume":"64","author":"Goldsmith","year":"2004","journal-title":"Drugs"},{"key":"10.1002\/jps.21179_bb0790","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/01.qco.0000191508.48481.f4","article-title":"Comparison of the efficacy and pharmacology of formulations of amphotericin B used in treatment of leishmaniasis","volume":"18","author":"Barrat","year":"2005","journal-title":"Curr Opin Infect Dis"},{"key":"10.1002\/jps.21179_bb0795","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: Conventional versus lipid formulations","volume":"38","author":"Sundar","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1002\/jps.21179_bb0800","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1086\/500138","article-title":"Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis","volume":"42","author":"Sundar","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1002\/jps.21179_bb0805","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2174\/138955706775476037","article-title":"New formulations and derivatives of amphotericin B for treatment of leishmaniosis","volume":"6","author":"Golenser","year":"2006","journal-title":"Mini Rev Med Chem"},{"key":"10.1002\/jps.21179_bb0810","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/srin.2001.29298","article-title":"Intrathecal amphotericin in the management of coccidioidal meningitis","volume":"16","author":"Stevens","year":"2001","journal-title":"Semin Respir Infect"},{"key":"10.1002\/jps.21179_bb0815","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1097\/00007611-199312000-00009","article-title":"Neonatal fungemia and amphotericin B","volume":"86","author":"Glick","year":"1993","journal-title":"South Med J"},{"key":"10.1002\/jps.21179_bb0820","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/00006454-199811000-00008","article-title":"Management of neonatal candidiasis. Neonatal Candidiasis Study Group","volume":"17","author":"Rowen","year":"1998","journal-title":"Pediatr Infect Dis J"},{"key":"10.1002\/jps.21179_bb0825","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1345\/aph.10240","article-title":"Amphotericin B\u2014Not so terrible","volume":"35","author":"Bishara","year":"2001","journal-title":"Ann Pharmacother"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916326119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354916326119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,3]],"date-time":"2019-05-03T03:43:44Z","timestamp":1556855024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354916326119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":164,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S0022354916326119"],"URL":"https:\/\/doi.org\/10.1002\/jps.21179","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}